Anti-CTLA4 mAbs Ipilimumab | Stage III and Metastatic melanoma |
Anti-PD-L1 mAbs Atezolizumab | 2nd line regiment for metastatic nonsmall-cell lung cancer Advanced or metastatic urothelial carcinoma |
Avelumab | Advanced or metastatic urothelial carcinoma Metastatic Merkel cell carcinoma |
Durvalumab | Advanced or metastatic urothelial carcinoma |
Anti-PD-1 mAbs Nivolumab | Metastatic melanoma 2nd line metastatic regiment of nonsmall-cell lung cancer 2nd line regiment of metastatic renal cell carcinoma Refractory classical Hodgkin lymphoma Recurrent or metastatic squamous cell carcinoma of the head and neck Advanced or metastatic urothelial carcinoma |
Pembrolizumab | Metastatic melanoma 1st and 2nd line regiment for metastatic nonsmall-cell lung cancer Advanced or metastatic renal cell carcinoma Refractory classical Hodgkin lymphoma MSI-high or MMR-deficient metastatic solid tumors Advanced or metastatic urothelial carcinoma |